YK-11 is a steroidal compound with a unique dual mechanism that distinguishes it from non-steroidal SARMs. While it binds to the androgen receptor as a partial agonist, it also inhibits myostatin by upregulating Follistatin — a mechanism that no other commercially available SARM shares.
YK-11 was first described by Kanno et al. in 2011 (Biological and Pharmaceutical Bulletin). The compound is derived from a C-19 steroid (related to DHT in its backbone) and acts as a partial agonist at the androgen receptor. Unlike most SARMs, YK-11 has structural similarities to 5α-dihydrotestosterone (DHT) at its steroidal core.
The myostatin inhibition mechanism is the compound's most distinctive feature. YK-11 stimulates muscle cells to produce more Follistatin — a protein that binds and neutralises myostatin. Myostatin (GDF-8) is a transforming growth factor that limits muscle fibre size. Inhibiting myostatin via Follistatin upregulation theoretically removes a natural ceiling on muscle growth — a mechanism distinct from direct AR activation.
The primary published in vitro study (Kanno et al., 2013) used C2C12 myoblast cell cultures and demonstrated that YK-11 induced greater Follistatin mRNA and protein expression than DHT at equivalent concentrations, and promoted greater myoblast differentiation. This in vitro data established the Follistatin/myostatin mechanism as the basis for YK-11's classification as a myostatin inhibitor.
It is important to note that published evidence for YK-11 does not extend to in vivo animal models or human clinical trials in the peer-reviewed literature. The Kanno in vitro data represents essentially the complete published preclinical scientific record for this compound. This is a critical caveat: YK-11's profile in living organisms — including pharmacokinetics, in vivo potency, suppression characteristics, and safety — is not established in published literature.
The anabolic potential implied by its dual mechanism (AR agonism + myostatin inhibition) is significant in theory. However, because in vivo and human data are absent from published literature, claims about YK-11's comparative potency cannot be substantiated with published evidence. Caution is appropriate given the lack of in vivo safety data.
Given its AR agonist activity, testosterone suppression is expected. The degree of suppression is not established in formal published studies. Based on its potency characteristics, researchers typically treat YK-11 protocols as requiring post-cycle support.
Two things: its steroidal backbone (unlike the non-steroidal scaffold of most SARMs) and its Follistatin-mediated myostatin inhibition. No other commercially available SARM simultaneously targets both the AR and the myostatin pathway in published research. This dual mechanism is theoretically compelling but remains largely in the domain of in vitro evidence.
